Sign In
Buy LLY
$1,083.23
+18.39 (+1.73%)
At Close: Jun 03, 2026
ADP Jobs Lower, Q4 Earnings Reports Up
11:22am, Wednesday, 04'th Feb 2026
Fresh Q4 earnings reports and private-sector jobs numbers are giving something of a jolt to market indexes.
Nasdaq closes deep in the red while Dow climbs with Alphabet earnings on deck
11:16am, Wednesday, 04'th Feb 2026
4:15pm: AI-fueled selloff Wall Street wrapped up a mixed session on Friday, with investors digesting a fresh wave of earnings and bracing for Alphabet’s...
Eli Lilly Stock Eyes Best Day Since October After Quarterly Beat
10:52am, Wednesday, 04'th Feb 2026
Eli Lilly And Co ( NYSE:LLY) stock is up 7.7% to trade at $1,080.69 at last glance, after the pharmaceutical name reported a top- and bottom-line beat for the fourth quarter and issued an upbeat forec
Eli Lilly shares soar after Q4 beat, strong forecast on weight-loss drugs
10:42am, Wednesday, 04'th Feb 2026
Eli Lilly and Co (NYSE:LLY) shares surged 9.5% in Wednesday morning trading after the drugmaker posted fourth-quarter results that topped Wall Street expectations and issued a robust forecast for 2026
3 Reasons A Pullback In Eli Lilly Stock Is Likely
10:40am, Wednesday, 04'th Feb 2026
Eli Lilly (LLY) is encountering challenges. Even well-established companies are not immune to corrections.
Eli Lilly Stock Jumps on Strong Weight-Loss Drug Outlook
09:32am, Wednesday, 04'th Feb 2026
Eli Lilly (LLY) shares climbed about 7% in early trading on Wednesday after the drugmaker issued a revenue outlook that topped market expectations, supported by
Stock Market Today: Futures Mixed After Indexes Tumble; AMD Shares Sink; Gold Moves Back Above $5,000
09:30am, Wednesday, 04'th Feb 2026
Stock futures pointed to a mixed open Wednesday, a day after major indexes sank as technology shares sold off. Meanwhile, gold and silver futures continued to rebound after retreating from recent high
Eli Lilly Says Weight Loss Pill On Track for 2Q Launch in US
09:27am, Wednesday, 04'th Feb 2026
Eli Lilly Chief Financial Officer Lucas Montarce says their weight loss pill is on track to launch in the US in the second quarter, pending approval by the Federal Drug Administration. Montarce says
Stock Futures Mixed as Wall Street Unpacks Earnings, Jobs Data
09:20am, Wednesday, 04'th Feb 2026
Stock futures are mixed as investors unpack earnings, in addition to weak private payrolls data
Eli Lilly (LLY) Q4 Earnings and Revenues Beat Estimates
08:56am, Wednesday, 04'th Feb 2026
Eli Lilly (LLY) came out with quarterly earnings of $7.54 per share, beating the Zacks Consensus Estimate of $6.99 per share. This compares to earnings of $5.32 per share a year ago.
Mounjaro Maker Eli Lilly Banks On Bigger 2026 Thanks To Weight Loss Drugs
08:39am, Wednesday, 04'th Feb 2026
Eli Lilly and Co. (NYSE: LLY) stock is trading higher after the company released better-than-expected Q4 earnings and issued fiscal 2026 guidance.
First Look: Lilly jumps; Novo warns; Walmart tops $1T
07:38am, Wednesday, 04'th Feb 2026
Stock News Lilly beats and lifts outlook: Eli Lilly (LLY) posted Q4 revenue of $19.29B (+43%) and adjusted EPS of $7.54, and guided 2026 revenue to $80â$83B a
Lilly says Mounjaro and Zepbound sales grew by at least 110% as stock rallies
07:21am, Wednesday, 04'th Feb 2026
The drugmaker also detailed strong growth for 2026
Eli Lilly sees 2026 profit above estimates on weight‑loss drug demand
06:51am, Wednesday, 04'th Feb 2026
Eli Lilly forecast 2026 profit above Wall Street estimates on Wednesday, as it expects strong demand for its blockbuster weight-loss and diabetes drugs, Zepbound and Mounjaro, to offset pricing pressu
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance
06:45am, Wednesday, 04'th Feb 2026
Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound. Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-G
